Viatris Retained Earnings (Accumulated Deficit) 2010-2024 | VTRS
Viatris retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Viatris retained earnings (accumulated deficit) for the quarter ending June 30, 2024 were $4.134B, a 23.01% decline year-over-year.
- Viatris retained earnings (accumulated deficit) for 2023 were $4.64B, a 10.35% decline from 2022.
- Viatris retained earnings (accumulated deficit) for 2022 were $5.176B, a 40.31% increase from 2021.
- Viatris retained earnings (accumulated deficit) for 2021 were $3.689B, a 31.19% decline from 2020.
| Viatris Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2023 | $4,640 |
| 2022 | $5,176 |
| 2021 | $3,689 |
| 2020 | $5,361 |
| 2019 | $6,031 |
| 2018 | $6,011 |
| 2017 | $5,645 |
| 2016 | $4,942 |
| 2015 | $4,462 |
| 2014 | $3,615 |
| 2013 | $2,685 |
| 2012 | $2,061 |
| 2011 | $1,421 |
| 2010 | $884 |
| 2009 | $660 |
| Viatris Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024-06-30 | $4,134 |
| 2024-03-31 | $4,608 |
| 2023-12-31 | $4,640 |
| 2023-09-30 | $5,553 |
| 2023-06-30 | $5,369 |
| 2023-03-31 | $5,253 |
| 2022-12-31 | $5,176 |
| 2022-09-30 | $4,313 |
| 2022-06-30 | $4,107 |
| 2022-03-31 | $3,942 |
| 2021-12-31 | $3,689 |
| 2021-09-30 | $4,087 |
| 2021-06-30 | $3,910 |
| 2021-03-31 | $4,324 |
| 2020-12-31 | $5,361 |
| 2020-09-30 | $6,277 |
| 2020-06-30 | $6,092 |
| 2020-03-31 | $6,052 |
| 2019-12-31 | $6,031 |
| 2019-09-30 | $6,011 |
| 2019-06-30 | $5,821 |
| 2019-03-31 | $5,989 |
| 2018-12-31 | $6,011 |
| 2018-09-30 | $5,966 |
| 2018-06-30 | $5,789 |
| 2018-03-31 | $5,752 |
| 2017-12-31 | $5,645 |
| 2017-09-30 | $5,394 |
| 2017-06-30 | $5,306 |
| 2017-03-31 | $5,009 |
| 2016-12-31 | $4,942 |
| 2016-09-30 | $4,525 |
| 2016-06-30 | $4,644 |
| 2016-03-31 | $4,476 |
| 2015-12-31 | $4,462 |
| 2015-09-30 | $4,268 |
| 2015-06-30 | $3,839 |
| 2015-03-31 | $3,671 |
| 2014-12-31 | $3,615 |
| 2014-09-30 | $3,425 |
| 2014-06-30 | $2,926 |
| 2014-03-31 | $2,801 |
| 2013-12-31 | $2,685 |
| 2013-09-30 | $2,505 |
| 2013-06-30 | $2,346 |
| 2013-03-31 | $2,168 |
| 2012-12-31 | $2,061 |
| 2012-09-30 | $1,899 |
| 2012-06-30 | $1,688 |
| 2012-03-31 | $1,550 |
| 2011-12-31 | $1,421 |
| 2011-09-30 | $1,291 |
| 2011-06-30 | $1,134 |
| 2011-03-31 | $988 |
| 2010-12-31 | $884 |
| 2010-09-30 | $881 |
| 2010-06-30 | $773 |
| 2010-03-31 | $721 |
| 2009-12-31 | $660 |
| 2009-09-30 | $656 |
| 2009-06-30 | $696 |
| 2009-03-31 | $638 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $14.203B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $125.093B | 15.25 |
| Cencora (COR) | United States | $45.021B | 17.20 |
| ICON (ICLR) | Ireland | $24.951B | 22.42 |
| DiDi Global (DIDIY) | China | $18.956B | 0.00 |
| Avantor (AVTR) | United States | $18.396B | 27.90 |
| Natera (NTRA) | United States | $15.720B | 0.00 |
| Revvity (RVTY) | United States | $15.367B | 26.91 |
| CochLear (CHEOY) | Australia | $12.751B | 0.00 |
| Solventum (SOLV) | United States | $12.458B | 0.00 |
| Medpace Holdings (MEDP) | United States | $11.201B | 33.99 |
| Charles River Laboratories (CRL) | United States | $10.641B | 20.11 |
| Sonic Healthcare (SKHHY) | Australia | $8.811B | 0.00 |
| Doximity (DOCS) | United States | $7.438B | 47.13 |
| Bausch + Lomb (BLCO) | Canada | $7.041B | 30.30 |
| HealthEquity (HQY) | United States | $6.771B | 36.75 |
| PACS (PACS) | United States | $6.218B | 0.00 |
| Organon (OGN) | United States | $5.142B | 5.23 |
| Life Times (LTH) | United States | $4.879B | 40.78 |
| Sotera Health (SHC) | United States | $4.741B | 23.91 |
| Surgery Partners (SGRY) | United States | $4.088B | 45.30 |
| Concentras Parent (CON) | United States | $2.955B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $2.789B | 105.00 |
| BrightSpring Health Services (BTSG) | United States | $2.550B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.438B | 0.00 |
| Progyny (PGNY) | United States | $2.206B | 38.79 |
| Alignment Healthcare (ALHC) | United States | $2.177B | 0.00 |
| Premier (PINC) | United States | $2.052B | 9.23 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.921B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.778B | 8.93 |
| Agilon Health (AGL) | United States | $1.642B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.556B | 0.00 |
| CareDx (CDNA) | United States | $1.543B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.183B | 0.00 | |
| GeneDx Holdings (WGS) | United States | $1.044B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.933B | 24.43 |
| Pediatrix Medical (MD) | United States | $0.933B | 10.15 |
| Embecta (EMBC) | United States | $0.895B | 5.97 |
| InnovAge Holding (INNV) | United States | $0.812B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.551B | 0.00 |
| Sharecare (SHCR) | United States | $0.527B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.499B | 0.00 |
| Enhabit (EHAB) | United States | $0.410B | 35.48 |
| Sonida Senior Living (SNDA) | United States | $0.370B | 0.00 |
| DocGo (DCGO) | United States | $0.361B | 13.58 |
| Sera Prognostics (SERA) | United States | $0.261B | 0.00 |
| Biodesix (BDSX) | United States | $0.253B | 0.00 |
| LifeMD (LFMD) | United States | $0.226B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.194B | 0.00 |
| ModivCare (MODV) | United States | $0.192B | 6.11 |
| Beauty Health (SKIN) | United States | $0.187B | 0.00 |
| MultiPlan (MPLN) | United States | $0.152B | 0.00 |
| Nutex Health (NUTX) | United States | $0.126B | 0.00 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.083B | 0.00 |
| So-Young (SY) | China | $0.081B | 19.72 |
| Singular Genomics Systems (OMIC) | United States | $0.042B | 0.00 |
| NeueHealth (NEUE) | United States | $0.042B | 1.66 |
| Co-Diagnostics (CODX) | United States | $0.041B | 0.00 |
| OncoCyte (OCX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.030B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.028B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.026B | 0.00 |
| Oncology Institute (TOI) | United States | $0.023B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.021B | 0.00 |
| TRxADE HEALTH (MEDS) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.010B | 0.00 |
| KindlyMD (KDLY) | $0.008B | 0.00 | |
| BioNexus Gene Lab (BGLC) | $0.008B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |